, de l'incidence et de la mortalité en France métropolitaine en 2017 -Rapport technique -Ref : RAINCMETRO17 | Institut National Du Cancer, 2018.

A. Volpe, T. Panzarella, R. A. Rendon, M. A. Haider, F. I. Kondylis et al., The natural history of incidentally detected small renal masses. Cancer, vol.100, pp.738-783, 2004.

A. Mathew, S. S. Devesa, J. F. Fraumeni, and W. Chow, Global increases in kidney cancer incidence, 1973-1992, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.11, issue.2, pp.171-179, 2002.

D. C. Johnson, J. Vukina, A. B. Smith, A. Meyer, S. B. Wheeler et al., Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate, J Urol, vol.193, issue.1, pp.30-35, 2015.

D. A. Kunkle, B. L. Egleston, and R. G. Uzzo, Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review, J Urol, vol.179, issue.4, pp.1233-1237, 2008.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, vol.356, issue.2, pp.115-139, 2007.

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, vol.356, issue.22, pp.2271-81, 2007.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, vol.372, issue.9637, pp.449-56, 2008.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, A. Frontera, O. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.378, issue.14, pp.1277-90, 2018.

B. Ljungberg, N. C. Cowan, D. C. Hanbury, M. Hora, M. A. Kuczyk et al., EAU guidelines on renal cell carcinoma: the 2010 update, Eur Urol, vol.58, issue.3, pp.398-406, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00511115

D. Heng, W. Xie, M. M. Regan, M. A. Warren, A. R. Golshayan et al., Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.34, pp.5794-5803, 2009.

M. Jayson and H. Sanders, Increased incidence of serendipitously discovered renal cell carcinoma, Urology, vol.51, issue.2, pp.203-208, 1998.

G. M. Israel and M. A. Bosniak, How I do it: evaluating renal masses, Radiology, vol.236, issue.2, pp.441-50, 2005.

L. Marconi, S. Dabestani, T. B. Lam, F. Hofmann, F. Stewart et al., Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy, Eur Urol, vol.69, issue.4, pp.660-73, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01262680

K. M. Tan, M. Shishkov, A. Chee, M. B. Applegate, B. E. Bouma et al., Flexible transbronchial optical frequency domain imaging smart needle for biopsy guidance, Biomed Opt Express, vol.3, issue.8, pp.1947-54, 2012.

Y. Xiong, Y. Mo, Y. Wen, M. Cheng, S. Huo et al., Optical coherence tomography for the diagnosis of malignant skin tumors: a meta-analysis, J Biomed Opt, vol.23, issue.2, pp.1-10, 2018.

K. Barwari, D. M. De-bruin, D. J. Faber, T. G. Van-leeuwen, J. J. De-la-rosette et al., Differentiation between normal renal tissue and renal tumours using functional optical coherence tomography: a phase I in vivo human study, BJU Int, vol.110, issue.8, pp.415-435, 2012.

M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, issue.10, pp.883-92, 2012.

A. Ingels, E. Barret, R. Sanchez-salas, M. Galiano, F. Rozet et al., Percutaneous Renal Biopsies for Small Renal Masses: Complex Tumors on Nephrometry Should Be the First Targets, Clin Genitourin Cancer, 2016.

T. Nakatani, N. Yoshida, H. Iwata, K. Kuratsukuri, J. Uchida et al., Clinicopathological study of renal cell carcinoma, Oncol Rep, vol.10, issue.3, pp.679-85, 2003.

I. Frank, M. L. Blute, J. C. Cheville, C. M. Lohse, A. L. Weaver et al., Solid renal tumors: an analysis of pathological features related to tumor size, J Urol, vol.170, issue.6, pp.2217-2237, 2003.

M. M. Nguyen and I. S. Gill, Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality, J Urol, vol.181, issue.3, pp.1020-1027, 2009.

W. Lowrance, S. Larson, and A. Anis-alibozek, Real-world presurgical characteristics and postsurgical morbidity of 10,404 Americans undergoing nephrectomy for renal tumors, International Kidney Cancer Symposium, 2011.

J. Schmidbauer, M. Remzi, M. Memarsadeghi, A. Haitel, H. C. Klingler et al., Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses, Eur Urol, vol.53, issue.5, pp.1003-1014, 2008.

E. Lechevallier, M. André, D. Barriol, L. Daniel, C. Eghazarian et al., Fineneedle percutaneous biopsy of renal masses with helical CT guidance, Radiology, vol.216, issue.2, pp.506-516, 2000.

Y. Neuzillet, E. Lechevallier, M. Andre, L. Daniel, and C. Coulange, Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses, J Urol, vol.171, issue.5, pp.1802-1807, 2004.

A. Volpe, A. Finelli, I. S. Gill, M. Jewett, G. Martignoni et al., Rationale for percutaneous biopsy and histologic characterisation of renal tumours, Eur Urol, 2012.

V. Phé, D. R. Yates, R. Renard-penna, O. Cussenot, and M. Rouprêt, Is there a contemporary role for percutaneous needle biopsy in the era of small renal masses? BJU Int, vol.109, pp.867-72, 2012.

L. Marconi, S. Dabestani, T. B. Lam, F. Hofmann, F. Stewart et al., Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy, Eur Urol, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01262680

C. J. Kane, K. Mallin, J. Ritchey, M. R. Cooperberg, and P. R. Carroll, Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer, vol.113, pp.78-83, 2008.

P. A. Smith, F. F. Marshall, and E. K. Fishman, Spiral computed tomography evaluation of the kidneys: state of the art, Urology, vol.51, issue.1, pp.3-11, 1998.

M. Remzi, M. Ozsoy, H. Klingler, M. Susani, M. Waldert et al., Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter, J Urol, vol.176, issue.3, pp.896-905, 2006.

A. Kutikov, R. G. Uzzo, and R. E. The, nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth, J Urol, vol.182, issue.3, pp.844-53, 2009.

H. M. Rosevear, P. T. Gellhaus, A. J. Lightfoot, T. P. Kresowik, F. N. Joudi et al., Utility of the RENAL nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk, BJU Int, vol.109, issue.5, pp.700-705, 2012.

A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter et al., Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score, Eur Urol, vol.60, issue.2, pp.241-249, 2011.

S. P. Stroup, K. Palazzi, R. P. Kopp, R. Mehrazin, M. Santomauro et al., RENAL nephrometry score is associated with operative approach for partial nephrectomy and urine leak, Urology, vol.80, issue.1, pp.151-157, 2012.

R. Mehrazin, K. L. Palazzi, R. P. Kopp, C. J. Colangelo, S. P. Stroup et al., Impact of tumour morphology on renal function decline after partial nephrectomy, BJU Int, vol.111, issue.8, pp.374-82, 2013.

G. D. Schmit, R. H. Thompson, A. N. Kurup, A. J. Weisbrod, S. A. Boorjian et al., Usefulness of R.E.N.A.L. nephrometry scoring system for predicting outcomes and complications of percutaneous ablation of 751 renal tumors, J Urol, vol.189, issue.1, pp.30-35, 2013.

C. A. Seideman, J. Gahan, M. Weaver, E. O. Olweny, M. Richter et al., Renal tumour nephrometry score does not correlate with the risk of radiofrequency ablation complications, BJU Int, vol.112, issue.8, pp.1121-1125, 2013.

Z. Okhunov, E. Y. Shapiro, D. M. Moreira, M. J. Lipsky, J. Hillelsohn et al., nephrometry score accurately predicts complications following laparoscopic renal cryoablation, J Urol, vol.188, issue.5, pp.1796-800, 2012.
DOI : 10.1016/j.juro.2012.07.028

M. L. Blute, Z. Okhunov, D. M. Moreira, A. K. George, S. Sunday et al., Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications, BJU Int, vol.111, issue.4, pp.181-186, 2013.

M. K. Samplaski, M. Zhou, B. R. Lane, B. Herts, and S. C. Campbell, Renal mass sampling: an enlightened perspective, Int J Urol Off J Jpn Urol Assoc, vol.18, issue.1, pp.5-19, 2011.
DOI : 10.1111/j.1442-2042.2010.02641.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1442-2042.2010.02641.x

P. G. Wagstaff, A. Ingels, D. M. De-bruin, M. Buijs, P. J. Zondervan et al., Percutaneous Needle Based Optical Coherence Tomography for the Differentiation of Renal Masses: a Pilot Cohort, J Urol, 2015.

A. Jemal, R. Siegel, J. Xu, and E. Ward, Cancer statistics, CA Cancer J Clin, vol.60, issue.5, pp.277-300, 2010.

G. Gandaglia, P. Ravi, F. Abdollah, A. Becker, A. Popa et al., Contemporary incidence and mortality rates of kidney cancer in the United States, Can Urol Assoc J J Assoc Urol Can, vol.8, issue.7-8, pp.247-52, 2014.

M. P. Laguna, F. Algaba, J. Cadeddu, R. Clayman, I. Gill et al., Current patterns of presentation and treatment of renal masses: a clinical research office of the endourological society prospective study, J Endourol, vol.28, issue.7, pp.861-70, 2014.

E. M. Hecht, G. M. Israel, G. A. Krinsky, W. Y. Hahn, D. C. Kim et al., Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging, Radiology, vol.232, issue.2, pp.373-381, 2004.

I. Millet, F. C. Doyon, D. Hoa, R. Thuret, S. Merigeaud et al., Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT?, AJR Am J Roentgenol, vol.197, issue.4, pp.887-96, 2011.

A. Volpe, J. A. Cadeddu, A. Cestari, I. S. Gill, M. Jewett et al., Contemporary management of small renal masses, Eur Urol, vol.60, issue.3, pp.501-516, 2011.
DOI : 10.1016/j.eururo.2011.05.044

P. Wagstaff, P. J. Zondervan, J. De-la-rosette, and M. P. Laguna, The role of imaging in the active surveillance of small renal masses, Curr Urol Rep, vol.15, issue.3, p.386, 2014.

P. G. Wagstaff, A. Swaan, A. Ingels, P. J. Zondervan, O. M. Van-delden et al., In vivo, percutaneous, needle based, optical coherence tomography of renal masses, J Vis Exp JoVE, issue.97, 2015.

M. J. Grundeken, H. M. Garcia-garcia, R. P. Kraak, P. Woudstra, D. M. De-bruin et al., Side branch healing patterns of the Tryton dedicated bifurcation stent: a 1-year optical coherence tomography follow-up study, Int J Cardiovasc Imaging, vol.30, issue.8, pp.1445-56, 2014.

J. R. Mourant, J. P. Freyer, A. H. Hielscher, A. A. Eick, D. Shen et al., Mechanisms of light scattering from biological cells relevant to noninvasive optical-tissue diagnostics, Appl Opt, vol.37, issue.16, pp.3586-93, 1998.

T. Xie, M. Zeidel, and Y. Pan, Detection of tumorigenesis in urinary bladder with optical coherence tomography: optical characterization of morphological changes. Opt Express, vol.10, pp.1431-1474, 2002.

B. J. Vakoc, D. Fukumura, R. K. Jain, and B. E. Bouma, Cancer imaging by optical coherence tomography: preclinical progress and clinical potential, Nat Rev Cancer, vol.12, issue.5, pp.363-371, 2012.

E. Cauberg, D. M. De-bruin, D. J. Faber, T. M. De-reijke, M. Visser et al., Quantitative measurement of attenuation coefficients of bladder biopsies using optical coherence tomography for grading urothelial carcinoma of the bladder, J Biomed Opt, vol.15, issue.6, p.66013, 2010.

M. Bus, B. G. Muller, D. M. De-bruin, D. J. Faber, G. M. Kamphuis et al., Volumetric in vivo visualization of upper urinary tract tumors using optical coherence tomography: a pilot study, J Urol, vol.190, issue.6, pp.2236-2278, 2013.

R. Wessels, D. M. De-bruin, D. J. Faber, H. H. Van-boven, A. D. Vincent et al., Optical coherence tomography in vulvar intraepithelial neoplasia, J Biomed Opt, vol.17, issue.11, p.116022, 2012.

B. G. Muller, D. M. De-bruin, W. Van-den-bos, M. J. Brandt, J. F. Velu et al., Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography, J Med Imaging Bellingham Wash, vol.2, issue.3, p.37501, 2015.

P. M. Bossuyt, J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou et al., Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative, Radiology, vol.226, issue.1, pp.24-32, 2003.

M. H. Zweig and G. Campbell, Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine, Clin Chem, vol.39, issue.4, pp.561-77, 1993.

A. Ingels, M. Hew, F. Algaba, O. J. De-boer, R. Van-moorselaar et al., Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study, World J Urol, 2016.

B. Ljungberg, K. Bensalah, S. Canfield, S. Dabestani, F. Hofmann et al., EAU guidelines on renal cell carcinoma: 2014 update, Eur Urol, vol.67, issue.5, pp.913-937, 2015.
DOI : 10.1016/j.eururo.2015.01.005

URL : https://hal.archives-ouvertes.fr/hal-01260564

T. Rüdiger, H. Höfler, H. Kreipe, H. Nizze, U. Pfeifer et al., Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists, Am J Surg Pathol, vol.26, issue.7, pp.873-82, 2002.

P. I. Karakiewicz, A. Briganti, F. Chun, Q. Trinh, P. Perrotte et al., Multiinstitutional validation of a new renal cancer-specific survival nomogram, J Clin Oncol Off J Am Soc Clin Oncol, vol.25, issue.11, pp.1316-1338, 2007.

L. H. Sobin and C. C. Compton, TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer, vol.116, pp.5336-5345, 2010.

I. Sakai, H. Miyake, A. Takenaka, and M. Fujisawa, Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy, BJU Int, vol.104, issue.7, pp.942-948, 2009.

B. A. Gayed, R. F. Youssef, A. Bagrodia, O. M. Darwish, P. Kapur et al., Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma, BJU Int, vol.113, issue.4, pp.668-73, 2014.

S. Tang, C. Su, Y. Chen, Y. Lai, Y. Wu et al., MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells, Cancer Lett, vol.273, issue.1, pp.35-43, 2009.

G. Li, G. Feng, A. Gentil-perret, C. Genin, and J. Tostain, CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy, Clin Exp Metastasis, vol.24, issue.3, pp.149-55, 2007.

M. Bui, D. Seligson, K. Han, A. J. Pantuck, F. J. Dorey et al., Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.2, pp.802-813, 2003.

A. Luong-player, H. Liu, H. L. Wang, and F. Lin, Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues, Am J Clin Pathol, vol.141, issue.2, pp.219-244, 2014.

H. L. Kim, D. Seligson, X. Liu, N. Janzen, M. Bui et al., Using protein expressions to predict survival in clear cell renal carcinoma, Clin Cancer Res Off J Am Assoc Cancer Res, vol.10, issue.16, pp.5464-71, 2004.

E. Sabo, I. Miselevich, J. Bejar, M. Segenreich, M. Wald et al., The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma, Br J Urol, vol.80, issue.6, pp.864-872, 1997.

H. Moch, P. Schraml, L. Bubendorf, M. Mirlacher, J. Kononen et al., High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma, Am J Pathol, vol.154, issue.4, pp.981-987, 1999.

B. F. Skinnider, A. L. Folpe, R. A. Hennigar, S. D. Lim, C. Cohen et al., Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors, Am J Surg Pathol, vol.29, issue.6, pp.747-54, 2005.

S. Lee, J. , S. Kim, H. , B. Kim et al., Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth, J Surg Oncol, vol.84, issue.3, pp.166-72, 2003.

C. Wang, Z. Zhou, A. Holmqvist, H. Zhang, Y. Li et al., Survivin expression quantified by Image Pro-Plus compared with visual assessment, Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem, vol.17, issue.6, pp.530-535, 2009.

J. Gu, Y. Liang, L. Qiao, X. Li, X. Li et al., Expression analysis of URI/RMP gene in endometrioid adenocarcinoma by tissue microarray immunohistochemistry, Int J Clin Exp Pathol, vol.6, issue.11, pp.2396-403, 2013.

X. Zhang, H. Wang, and J. Wang, Expression of HMGB1 and NF-?B p65 and its significance in non-small cell lung cancer, Contemp Oncol Pozn Pol, vol.17, issue.4, pp.350-355, 2013.

J. G. Lu, Y. Li, L. Li, and X. Kan, Overexpression of osteopontin and integrin ?v in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis, J Cancer Res Clin Oncol, vol.137, issue.11, pp.1613-1621, 2011.

H. Shi, M. Hayes, C. Kirana, R. Miller, J. Keating et al., TUFM is a potential new prognostic indicator for colorectal carcinoma. Pathology (Phila), vol.44, pp.506-518, 2012.

J. Budczies, F. Klauschen, B. V. Sinn, B. Gy?rffy, W. D. Schmitt et al., Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization, PloS One, vol.7, issue.12, p.51862, 2012.

C. T. Nguyen and M. W. Kattan, How to tell if a new marker improves prediction, Eur Urol, vol.60, issue.2, pp.226-234, 2011.

S. Ivanov, S. Y. Liao, A. Ivanova, A. Danilkovitch-miagkova, N. Tarasova et al., Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer, Am J Pathol, vol.158, issue.3, pp.905-924, 2001.

C. A. Brewer, S. Y. Liao, S. P. Wilczynski, S. Pastorekova, J. Pastorek et al., A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN, Gynecol Oncol, vol.63, issue.3, pp.337-381, 1996.

J. R. Turner, R. D. Odze, C. P. Crum, and M. B. Resnick, MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancerassociated biomarker, Hum Pathol, vol.28, issue.6, pp.740-744, 1997.

J. Saarnio, S. Parkkila, A. K. Parkkila, K. Haukipuro, S. Pastoreková et al., Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation, Am J Pathol, vol.153, issue.1, pp.279-85, 1998.

A. B. Stillebroer, P. Mulders, O. C. Boerman, W. Oyen, and E. Oosterwijk, Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy, Eur Urol, vol.58, issue.1, pp.75-83, 2010.

E. Perlson, I. Michaelevski, N. Kowalsman, K. Ben-yaakov, M. Shaked et al., Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase, J Mol Biol, vol.364, issue.5, pp.938-982, 2006.

J. Sandlund, E. Oosterwijk, K. Grankvist, J. Oosterwijk-wakka, B. Ljungberg et al., Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma, BJU Int, vol.100, issue.3, pp.556-60, 2007.

J. Patard, P. Fergelot, P. I. Karakiewicz, T. Klatte, Q. Trinh et al., Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma, Int J Cancer J Int Cancer, vol.123, issue.2, pp.395-400, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00278587

T. Klatte, D. B. Seligson, J. Larochelle, B. Shuch, J. W. Said et al., Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.18, issue.3, pp.894-900, 2009.

L. True and Z. Feng, Immunohistochemical Validation of Expression Microarray Results, J Mol Diagn, vol.7, issue.2, pp.149-51, 2005.

I. Leguerney, L. De-rochefort, M. Poirier-quinot, A. Ingels, X. Violas et al., Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma, Contrast Media Mol Imaging, p.7498538, 2017.

M. Claudon, C. F. Dietrich, B. I. Choi, D. O. Cosgrove, M. Kudo et al., Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver -update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS, Ultrasound Med Biol, vol.39, issue.2, pp.187-210, 2013.

C. F. Dietrich, M. A. Averkiou, J. Correas, N. Lassau, E. Leen et al., An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion, Ultraschall Med Stuttg Ger, vol.33, issue.4, pp.344-51, 1980.

N. Lassau, S. Koscielny, L. Albiges, L. Chami, B. Benatsou et al., Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography, Clin Cancer Res Off J Am Assoc Cancer Res, vol.16, issue.4, pp.1216-1241, 2010.

J. O'connor, E. O. Aboagye, J. E. Adams, H. Aerts, S. F. Barrington et al., Imaging biomarker roadmap for cancer studies, Nat Rev Clin Oncol, vol.14, issue.3, pp.169-86, 2017.

N. Deshpande, M. A. Pysz, and J. K. Willmann, Molecular ultrasound assessment of tumor angiogenesis, Angiogenesis, vol.13, issue.2, pp.175-88, 2010.

F. Kiessling, S. Fokong, P. Koczera, W. Lederle, and T. Lammers, Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics, J Nucl Med Off Publ Soc Nucl Med, vol.53, issue.3, pp.345-353, 2012.

M. A. Mcateer and R. P. Choudhury, Targeted molecular imaging of vascular inflammation in cardiovascular disease using nano-and micro-sized agents, Vascul Pharmacol, vol.58, issue.1-2, pp.31-39, 2013.

A. H. Smith, H. Fujii, M. A. Kuliszewski, and H. Leong-poi, Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis, J Cardiovasc Transl Res, vol.4, issue.4, pp.404-419, 2011.

D. B. Ellegala, H. Leong-poi, J. E. Carpenter, A. L. Klibanov, S. Kaul et al., Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation, Jul, vol.22, issue.3, pp.336-377, 2003.

A. H. Schmieder, P. M. Winter, S. D. Caruthers, T. D. Harris, T. A. Williams et al., Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles, Magn Reson Med, vol.53, issue.3, pp.621-628, 2005.

T. Huo, X. Du, S. Zhang, X. Liu, and X. Li, Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin alphanubeta3 receptor-expressed tumor-MR molecular imaging of angiogenesis, Eur J Radiol, vol.73, issue.2, pp.420-427, 2010.

P. M. Winter, S. D. Caruthers, J. S. Allen, K. Cai, T. A. Williams et al., Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrintargeted nanoparticles, Magn Reson Med, vol.64, issue.2, pp.369-76, 2010.

I. Leguerney, N. Lassau, S. Koscielny, M. Rodrigues, C. Massard et al., Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments, Invest New Drugs, vol.30, issue.1, pp.144-56, 2012.

S. Lavisse, P. Lejeune, V. Rouffiac, N. Elie, E. Bribes et al., Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrastenhanced ultrasonography, Invest Radiol, vol.43, issue.2, pp.100-111, 2008.

N. Lassau, J. Bonastre, M. Kind, V. Vilgrain, J. Lacroix et al., Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study, Invest Radiol, vol.49, issue.12, pp.794-800, 2014.

N. Lassau, S. Koscielny, L. Chami, M. Chebil, B. Benatsou et al., Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results, Radiology, vol.258, issue.1, pp.291-300, 2011.

N. Lassau, D. Cosgrove, and A. , Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine, Future Oncol Lond Engl, vol.8, issue.10, pp.1215-1223, 2012.

O. M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner et al., Dynamic contrastenhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.28, pp.4572-4580, 2008.

F. A. Howe, S. P. Robinson, D. J. Mcintyre, M. Stubbs, and J. R. Griffiths, Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours, NMR Biomed, vol.14, issue.7-8, pp.497-506, 2001.

A. R. Padhani and M. O. Leach, Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging, Abdom Imaging, vol.30, issue.3, pp.324-365, 2005.
DOI : 10.1007/s00261-004-0265-5

A. Toschi, E. Lee, N. Gadir, M. Ohh, and D. A. Foster, Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2, J Biol Chem, vol.283, issue.50, pp.34495-34504, 2008.

C. Ravelli, S. Mitola, M. Corsini, and M. Presta, Involvement of ?v?3 integrin in gremlin-induced angiogenesis, Angiogenesis, vol.16, issue.1, pp.235-278, 2013.

J. S. Desgrosellier, L. A. Barnes, D. J. Shields, M. Huang, S. K. Lau et al., An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression, Nat Med, vol.15, issue.10, pp.1163-1172, 2009.
DOI : 10.1038/nm.2009

URL : http://europepmc.org/articles/pmc2759406?pdf=render

D. A. Sipkins, D. A. Cheresh, M. R. Kazemi, L. M. Nevin, M. D. Bednarski et al., Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging, Nat Med, vol.4, issue.5, pp.623-629, 1998.

A. Bex, L. Fournier, N. Lassau, P. Mulders, P. Nathan et al., Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations, Eur Urol, vol.65, issue.4, pp.766-77, 2014.

H. C. Kang, K. Tan, S. M. Keefe, D. F. Heitjan, E. S. Siegelman et al., MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib, AJR Am J Roentgenol, issue.1, pp.120-126, 0200.

P. Therasse, S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, vol.92, issue.3, pp.205-221, 2000.

M. Nishino, J. P. Jagannathan, and N. H. Ramaiya, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know, AJR Am J Roentgenol, vol.195, issue.2, pp.281-290, 2010.

H. Wang, A. M. Lutz, D. Hristov, L. Tian, and J. K. Willmann, Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrastenhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer, Radiology, vol.282, issue.2, pp.443-52, 2017.

M. Baron-toaldo, S. V. Marinelli, S. Palamà, C. Milazzo, M. Croci et al., Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma, Mol Imaging Biol MIB Off Publ Acad Mol Imaging, vol.17, issue.1, pp.29-37, 2015.

R. S. Eschbach, D. Clevert, H. Hirner-eppeneder, M. Ingrisch, M. Moser et al., Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation, PloS One, vol.12, issue.1, p.169323, 2017.

S. C. Baetke, A. Rix, F. Tranquart, R. Schneider, T. Lammers et al., Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects, Radiology, vol.278, issue.2, pp.430-470, 2016.

H. Wang, O. F. Kaneko, L. Tian, D. Hristov, and J. K. Willmann, Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer, Invest Radiol, vol.50, issue.5, pp.322-331, 2015.

M. A. Pysz, S. B. Machtaler, E. S. Seeley, J. J. Lee, T. A. Brentnall et al., Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection, Radiology, vol.274, issue.3, pp.790-799, 2015.

J. E. Streeter, S. G. Herrera-loeza, N. F. Neel, J. J. Yeh, and P. A. Dayton, A comparative evaluation of ultrasound molecular imaging, perfusion imaging, and volume measurements in evaluating response to therapy in patient-derived xenografts, Technol Cancer Res Treat, vol.12, issue.4, pp.311-332, 2013.

S. R. Sirsi, M. L. Flexman, F. Vlachos, J. Huang, S. L. Hernandez et al., Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy, Ultrasound Med Biol, vol.38, issue.6, pp.1019-1048, 2012.

J. Zhou, H. Wang, H. Zhang, A. M. Lutz, L. Tian et al., VEGFR2-Targeted ThreeDimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer, Cancer Res, vol.15, issue.14, pp.4081-4090, 2016.

J. D. Rojas, F. Lin, Y. Chiang, A. Chytil, D. C. Chong et al., Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy, Theranostics, vol.8, issue.1, pp.141-55, 2018.

A. E. Thong, H. Zhao, A. Ingels, M. P. Valta, R. Nolley et al., Tissue slice grafts of human renal cell carcinoma: An authentic preclinical model with high engraftment rate and metastatic potential, Urol Oncol, 2013.

I. Leguerney, J. Scoazec, N. Gadot, N. Robin, F. Pénault-llorca et al., Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin, Ultrasound Med Biol, vol.41, issue.1, pp.197-207, 2015.

J. K. Willmann, L. Bonomo, C. Testa, A. Rinaldi, P. Rindi et al., Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, pp.2133-2173, 2017.

M. Smeenge, F. Tranquart, C. K. Mannaerts, T. M. De-reijke, M. J. Van-de-vijver et al., First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study, Invest Radiol, vol.52, issue.7, pp.419-446, 2017.

A. Radu, C. Pichon, P. Camparo, M. Antoine, Y. Allory et al., Expression of follicle-stimulating hormone receptor in tumor blood vessels, N Engl J Med, vol.363, issue.17, pp.1621-1651, 2010.

M. A. Siraj, C. Pichon, A. Radu, and N. Ghinea, Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib, J Cell Mol Med, vol.16, issue.9, pp.2010-2016, 2012.

Y. Xu, D. Pan, C. Zhu, Q. Xu, L. Wang et al., Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging, Mol Imaging Biol MIB Off Publ Acad Mol Imaging, vol.16, issue.4, pp.578-85, 2014.

I. Minn, S. M. Koo, H. S. Lee, M. Brummet, S. P. Rowe et al., XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma, Oncotarget, vol.64, issue.35, pp.56471-56480, 2016.

X. Yang, I. Minn, S. P. Rowe, S. R. Banerjee, M. A. Gorin et al., Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor, Oncotarget, vol.6, issue.32, pp.33733-33775, 2015.

H. Honarvar, J. Garousi, E. Gunneriusson, I. Höidén-guthenberg, M. Altai et al., Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule, Int J Oncol, vol.46, issue.2, pp.513-533, 2015.